Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Intrauterine growth retardation (IUGR) has been linked to the development of Type 2 diabetes in adulthood. We have developed an IUGR model in the rat whereby the animals develop diabetes later in life. Previous studies demonstrate that administration of the long-acting glucagon-like-peptide-1 agonist, Exendin-4, during the neonatal period prevents the development of diabetes in IUGR rats. IUGR animals exhibit hepatic insulin resistance early in life (prior to the onset of hyperglycemia), characterized by blunted suppression of hepatic glucose production (HGP) in response to insulin. Basal HGP is also significantly higher in IUGR rats. We hypothesized that neonatal administration of Exendin-4 would prevent the development of hepatic insulin resistance. IUGR and control rats were given Exendin-4 on days 1–6 of life. Hyperinsulinemic-euglycemic clamp studies showed that Ex-4 significantly reduced basal HGP by 20% and normalized insulin suppression of HGP in IUGR rats. While Ex-4 decreased body weight and fat content in both Control and IUGR animals, these differences were only statistically significant in Controls. Exendin-4 prevented development of oxidative stress in liver and reversed insulin-signaling defects in vivo, thereby preventing the development of hepatic insulin resistance. Defects in glucose disposal and suppression of hepatic glucose production in response to insulin were reversed. Similar results were obtained in isolated Ex-4-treated neonatal hepatocytes. These results indicate that exposure to Exendin-4 in the newborn period reverses the adverse consequences of fetal programming and prevents the development of hepatic insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“Ex-4 shows a 53% amino acid sequence identity to GLP-1 (18) and shares many actions with GLP-1 via the GLP-1 receptor (37).”
BackgroundIntrauterine Growth Retardation Leads to the Development of Type 2 Diabetes in the Rat
Simmons, R. A., Templeton, L. J., & Gertz, S. J. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2279 · Cited by 638 · cited 1×
“The end result is the later development of diabetes in adulthood with the salient features of most forms of Type 2 diabetes (T2DM) in the human: defects in insulin action and insulin secretion (49).”
BackgroundSelf-citationVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 1×
“It is also possible that Ex-4 is mediating its actions in the IUGR neonate through GLP-1 receptors in the portal vein, as a number of investigators have shown that Ex-4 can reduce glucose, independent of islet hormones or gastric emptying (3, 4, 9, 28, 38, 39, 41, 57).”
BackgroundMeeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · cited 1×
“Despite the well-known suppressive effect of GLP-1 and Ex-4 on appetite (34), food intake was not affected by Ex-4 treatment, and daily caloric intake was similar among all groups between weaning (3 wk) and 8 wk of age ( 21–24 g rat 1 day (1)).”
BackgroundWheeler, M. B., Lu, M., Dillon, J. S., Leng, X. H., Chen, C., & Boyd, A. E. (1993) · Endocrinology · doi:10.1210/endo.133.1.8391428 · Cited by 225
Simmons, R. A., Suponitsky-Kroyter, I., & Selak, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505695200 · Cited by 194
Self-citation
Cited by
Diabetes, oxidative stress and therapeutic strategies
Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.017 · Cited by 530
Developmental origins of metabolic disease: Life course and intergenerational perspectives
Godfrey, K. M., Gluckman, P. D., & Hanson, M. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.12.008 · Cited by 485
Developmental origins of metabolic diseases
Hoffman, D. J., Powell, T. L., Barrett, E. S., & Hardy, D. B. (2021) · Physiological Reviews · doi:10.1152/physrev.00002.2020 · Cited by 466
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Developmental origins of health and disease: current knowledge and potential mechanisms
Hoffman, D. J., Reynolds, R. M., & Hardy, D. B. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux053 · Cited by 355
Metadata
- Authors
- Raab, E. L., Vuguin, P. M., Stoffers, D. A., & Simmons, R. A.
- Venue
- American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Publisher
- American Physiological Society
- Published
- 2009-12
- Volume
- 297
- Issue
- 6
- Pages
- R1785-R1794
- ISSN
- 0363-6119 (ISSN-L)
- 1522-1490
- OpenAlex
- W2013804474
- Cited by
- 57
- References
- 6
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. https://app.cochat.ai/papers/10.1152/ajpregu.00519.2009
- The paper
- Raab, E. L., Vuguin, P. M., Stoffers, D. A., & Simmons, R. A. (2009). Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. https://doi.org/10.1152/ajpregu.00519.2009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.